A draft protocol amendment is currently being reviewed by members of the trial management committee. The key proposed changes are to the dose escalation and toxicity management in the Imatinib 400mg daily plus Intrferon arm. If you have any queries regarding the proposed changes please contact Corinne.

Once the amendment has been approved by the ethics committee and the MHRA a full communication will be sent out to all participating sites, until this time please continue to use the current version of the protocol (vrsion 14).